Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...
-
Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing...
-
Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing...
-
Big Sky Asset Management Surpasses $100 Million in Acquisitions in 90 Days Across Five Transactions with Four Capital Partners
-
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
-
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
-
SHENZHEN, CHINA, March 05, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small...
-
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...
-
Dublin, March 04, 2026 (GLOBE NEWSWIRE) -- The "Pharma-Grade Hyaluronic Acid Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The pharma-grade...
-
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – –...